A Phase I, First-in-human, Open-label, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Patients With Advanced Solid Tumors
OPEN TO ACCRUAL
I
NCT06750185
benedito.carneiro@BrownHealth.org
